Combination of extracts from Aristolochia cymbifera with streptomycin as a potential antibacterial drug.
The appearance of new antibiotic-resistant bacteria is a societal problem that requires the development of new alternative treatments. Therefore, this work evaluated the antibacterial activity of ethanolic (EHI), dichloromethanic (EDI) and hexanic (EHE) extracts from Aristolochia cymbifera stems and...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2013 |
| País: | Brasil |
| Institución: | Universidade Federal de Ouro Preto (UFOP) |
| Repositorio: | Repositório Institucional da UFOP |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.ufop.br:123456789/4180 |
| Acceso en línea: | http://www.repositorio.ufop.br/handle/123456789/4180 https://doi.org/10.1186/2193-1801-2-430 |
| Access Level: | acceso abierto |
| Palabra clave: | Aristolochia cymbifera Antibacterial activity Synergism Cytotoxicity Drug discovery |
| Sumario: | The appearance of new antibiotic-resistant bacteria is a societal problem that requires the development of new alternative treatments. Therefore, this work evaluated the antibacterial activity of ethanolic (EHI), dichloromethanic (EDI) and hexanic (EHE) extracts from Aristolochia cymbifera stems and the combination of these extracts with an antimicrobial drug to develop a new antibacterial therapy. The EDI, EHE and EHI extracts were obtained by maceration using three different solvents. The minimal inhibitory concentrations (MIC) of these extracts were determined using the microdilution test to determine the antibacterial potential of these extracts and their combination with streptomycin against Staphylococcus aureus, Bacillus cereus, Klebsiella pneumoniae and Shigella flexneri. The extract dose leading to the cytotoxicity of 50% of the cells (CC50) was evaluated using mammalian cells MA104 and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. The extracts had a MIC under 500 mg/L and a CC50 lower than 50 mg/L. The antibiotic/extract proportion influenced the antibacterial activity of the mixtures, and the proportion that optimized the antibacterial activity of streptomycin was a mixture that contained 75 percent of extract. This composition included less than 6.5 mg/L of extract and 2.5 mg/L of streptomycin and has potential as a new antibacterial therapy. |
|---|